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Abstract 
 
The immediate-type allergic reaction is involved in many allergic diseases such as asthma, 
allergic rhinitis and sinusitis.  In this study, we investigated the effect of acteoside extracted 
from Cistanche tubulosa (Schrenk) R. Wight on the basophilic cell-mediated allergic reaction.  
The effect of acteoside on β-hexosaminidase release and intracellular [Ca2+]i level from rat 
basophilic leukemia (RBL-2H3) cells was determined.  Also, ELISA was used to determine 
the level of histamine, tumor necrosis factor (TNF)-α and interleukin (IL)-4 on human 
basophilic (KU812) cells.  The effect of acteoside on basophilic cell viability was 
determined using the 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide (MTT) assay.  
These results indicated that 0.1–10.0 µg/mL acteoside inhibit the release of β-hexosaminidase 
and [Ca
2+
]i influx from IgE-mediated RBL-2H3 cells.  Also acteoside inhibited histamine 
release, TNF-α and IL-4 production in a dose-dependent manner from calcium ionophore 
A23187 plus phorbol 12-myristate 13-acetate (PMA) or compound 48/80-stimulated KU812 
cells.  Our findings provide evidence that acteoside inhibits basophilic cell-derived 
immediate-type and layed-type allergic reactions.  This is the first report describing 
anti-allergic activity of acteoside extracted from Cistanche tubulosa on basophilic cells. 
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Abbreviations: 
IL-4:  interleukin-4 
KU812:  human basophilic cells 
MTT:  3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide 
PKC:  protein kinase C 
PMA:  phorbol 12-myristate 13-acetate 
RBL-2H3: rat basophilic leukemia cells 
TNF-α:  tumor necrosis factor-α 
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Introduction 
 
Herba Cistanchis is the whole herb of Orobanchaceae family, Cistanche genus, other names 
such as Da Yun, Cong Rong, Cun Rong also exist.  The herbs of the same genus named 
Cistanche tubulosa (Schrenk) R. Wight (Orobanchaceae) is a perennial parasitic plant 
growing on the roots of Salvadora or Calotropis species, and distributed in North Africa, 
Arabia and Asian countries.  It has been traditionally used as a blood circulation-promoting 
agent and in the treatment of impotence, sterility, lumbago, body weakness and tonic [1-2].  
Cistanche tubulosa extract has been shown to have effect on various brain diseases, anti-aging 
functions, metabolism of fat, and hair growth [3-6].  Recently, several compounds including 
iridoids, monoterponenoids, phenylethanoid glycosides such as acteoside, echinacoside and 
cistanoside A, and lignans were isolated from Chinese and Pakistan Cistanche tubulosa [1, 7].  
Some of these phenylethanoid glycosides appear to have various biological activities, such as 
anti-inflammatory anti-oxidant, and relaxation properties [8-10].  Moreover, acteoside 
extracted from Cistanche tubulosa regulated immunity on aging mice [11], also acteoside 
isolated from Clerodendron trichotomum thunberg have anti-inflammatory effect on 
melittin-stimulated RBL-2H3 cells [12], and lipopolysaccharide-stimulated mouse peritoneal 
macrophage [13].  Considerable data on the acteoside and echinacoside extracted from 
Cistanche tubulosa have been reported with the few studies on antioxidant effect.  However, 
their anti-allergic effects have not been studied. 
Type I allergy is induced by certain types of antigens such as foods, dust mites, medicines, 
pollen, and cosmetics.  This type of antigens induces production of antigen-specific IgE 
antibodies that bind to receptors on mast cells or basophilic cells.  Recently, the early phase 
and late phase reactions, have been reported in type I allergy.  The early phase reaction in 
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type I allergy occurs within a few minutes and then mediators such as histamine and serotonin 
are released from the cell.  The late phase reaction occurs hours after the early phase reaction 
in type I allergy, the mediators such as inflammatory cytokines TNF-α, IL-4, IL-6, IL-8, and 
IL-13 are secreted from the cells, respectively [14-16].  β-Hexosaminidase, which is stored 
in the secretiory granules of mast cells is released concomitantly with histamine when mast 
cells are immunologically activated.  Thus, β-hexosaminidase activity in the medium is used 
as a marker of mast cell degranulation [17-18].  RBL-2H3 cells have been extensively used 
for studying IgE–FcεRI (the high affinity IgE receptor) interactions [19], signaling pathways 
for degranulation [20], and gene expression of inflammatory cytokines [21].  RBL-2H3 cells 
are therefore considered as a good tool for studying the effect of unknown compounds on 
histamine release or β-hexosaminidase release activity. 
Basophils and mast cells types originate from the hematopoietic stem cells and share several 
biochemical and functional properties.  Human mast cells are useful cells for studying 
synthesis of mediators and cytokine activation pathway because they secrete histamine and 
many inflammatory cytokines, when stimulated with phorbol esters and calcium ionophore 
A23187 [22-23].  Both basophils and mast cells play a major role in the pathogenesis of 
inflammatory diseases by releasing several pro-inflammatory mediators [24].  Activated 
mast cells can produce histamine, as well as wide variety of other inflammatory mediators 
such as eicosanoids, proteoglycans, proteases and several proinflammatory and chemotactic 
cytokines such as TNF-α, IL-6, IL-4, IL-8, and IL-13.  Therefore, modulation of secretion of 
these cytokines from mast cells can provide a useful therapeutic strategy for allergic 
inflammatory disease [23, 25]. 
In this study, we investigated inhibition effect of three phenylethanoid glycosides derived 
from Cistanche tubulosa on β-hexosaminidase release by IgE-mediated RBL-2H3 cells as 
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type I allergy model, and inhibition effect of acteoside on histamine release from A23187 plus 
PMA or compound 48/80-stimulated KU812 cells, and on cytokines production by the same 
cell line. 
 
Materials and methods 
 
Cell lines, chemicals and biochemicals 
RBL-2H3 cells were purchased from JCRB Cell Bank, Japan.  The cells were maintained in 
MEM supplemented with 10%FBS and 2 mM L-glutamine, while KU812 cells were 
purchased from Riken Cell Bank, Japan.  The cells were maintained in a RPMI 1640 
medium supplemented with 10%FBS, and the cells incubated at 37
o
C in a 5%CO2 incubator.  
Dinitrophenylated bovine serum albumin (DNP-BSA) was purchased from Cosmo 
Biotechnology Co., Ltd.  Anti-DNP-IgE, ketotifen fumarate salt (>99%), L-glutamine, 
calcium ionophore A23187, PMA and compound 48/80 were purchased from Sigma-Aldrich.  
Fetal bovine serum (FBS) was purchased from Hyclone Co., Ltd.  Eagle’s Minimum 
Essential Medium (MEM) was purchased from Nissui Pharmaceutical Co., Ltd.  
3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide (MTT) was purchased from 
Dojindo. Co., Ltd. 
 
Plant material 
The stems of Cistanche tubulosa (Orobanchaceae) were purchased from Shinwa Bussan Co., 
Ltd, in Osaka, Japan and identified by botany expert, and their voucher specimens 
(UT-CT040401) were deposited in the Graduate School of Life and Environmental Sciences, 
University of Tsukuba, Ibaraki, Japan. 
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Extraction and isolation 
The stems of Cistanche tubulosa (500 g) were extracted with MeOH (1.5 l), and evaporated to 
dryness in vacuo at 30°C.  The MeOH extract was partitioned between EtOAc (1.0 L × 3) 
and H2O (1.0 L) and then the H2O layer was partitioned with n-BuOH (1.0 L × 3).  The 
n-BuOH-soluble portion (3.1 g) was subjected to a ODS column (Cosmosil ODS, 2.2 x 30 cm, 
MeOH/H2O, 3:7→1:0) to separate twelve fractions (CT-BU-1~12) including echinacoside 
(CT-BU-9, 25.4 mg).  CT-BU-10 (491 mg) was applied to a silica gel column (2.2 × 30 cm, 
CHCl3/MeOH/H2O, 80:25:3) to afford thirteen fractions (CT-BU-10-1~13) including 
cistanoside A (CT-BU-10-11, 86.2 mg), and using a silica gel column (2.2 × 30 cm, 
CHCl3/MeOH/H2O, 80:25:3) to obtain acteoside (12.1 mg) from CT-BU-10-9 fraction.  The 
purity (>90%) of these three phenylethanoid glycosides, acteoside, echinacoside, and 
cistanoside A were determined by the high performance liquid chromatography (HPLC) and 
nuclear magnetic resonance (NMR) spectra.  The three compounds were identified by 
comparisons of the 
1
H and 
13
C NMR data with those previously reported in the literatures.  
Chemical structures of three phenylethanoid glycosides extracted from Cistanche tubulosa are 
shown in Fig. 1. 
 
MTT assay 
The MTT assay is a sensitive and quantitative colorimetric assay that is used to determine cell 
viability [26].  RBL-2H3 cells and KU812 cells were harvested at approximately 60-80% 
confluence and seed onto 96-well plate at 5.0 × 10
4
 cells/well in 100 µL medium.  After an 
overnight incubation, the cells were washed twice with PBS (-) and 100 µL of medium with 
three phenylethanoid glycosides (0.1-100.0 µg/mL) was added.  The cells were incubated for 
48 h, before 10 µL of 5 mg/mL of MTT added.  After 24 h of incubation, 180 µL of 10% 
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sodium dodecyl sulfate (SDS) was added, this being followed by another 24 h of incubation to 
completely dissolve the formazan produced by the cells.  The absorbance was then 
determined at 570 nm with a microplate reader (Power Scan HT, Dainippon Pharmaceutical 
Co., Ltd.).  Blanks were also prepared at the same treatment.  The optical density of the 
formazan produced by the untreated control cells was considered as representing 100% 
viability. 
 
β-Hexosaminidase release assay 
The β-hexosaminidase release inhibition assay using RBL-2H3 cells was performed as 
previously described [26].  RBL-2H3 cells were seeded onto 96-well plates (Falcon Co.) at 
5.0 × 10
4
 cells/well in 100 µL of medium.  The cells were incubated for 24 h at 37
o
C and 
sensitized with 0.3 µg/mL anti-DNP-IgE, then washed twice with PBS (-) to eliminate free 
IgE.  After incubating the cells at 37
o
C for 10 min in 60 µL per well of a releasing mixture 
containing 5 µL of three phenylethanoid glycosides (0.1-10.0 µg/mL), the cells were exposed 
to 0.3 µg/mL DNP-BSA in PBS (-) followed by incubation at 37
o
C for 1 h.  For positive and 
negative controls, 3 mM ketotifen fumarate salt (Keto.) and PBS (-) were used, respectively.  
Then, 80 µL of substrate solution was then added to 20 µL of the supernatant followed by 
incubation at 37
o
C for 30 min.  After adding 100 µL/well of stop buffer, the absorbance at 
405 nm was obtained using a microplate reader.  The percentage of β-hexosaminidase 
released was calculated using the following equation:  
β-hexosaminidase release (%) = {(T-Bt) / (C-Bc)} × 100 
Control (C): Cell (+), DNP-BSA (+), test sample (-); Test (T): Cell (+), DNP-BSA (+), test 
sample (+); Blankt (Bt): Cell (-), DNP-BSA (+), test sample (+); Blankc (Bc): Cell (-), 
DNP-BSA (+), test sample (-). 
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Determination of intracellular [Ca
2+
]i level 
[Ca
2+
]i measurement was performed by the method of Aase and Arna [27]  with some 
modifications.  RBL-2H3 cells (5.0×10
4
 cells per well in 100 µL of medium) were 
precultured at 37
o
C for 24 h in 96-well plates using a medium containing 10%FBS and 0.3 
μg/mL anti-DNP IgE.  The cells were washed twice with 200 µL of PBS (-) to eliminate free 
IgE.  The cells were then incubated with 100 µL per well of loading buffer containing 
Fluo3-AM (Calcium Kit-Fluo3, Dojindo Co., Ltd.) at 37
o
C for 1 h.  The cells were then 
washed twice with 200 µL of PBS (-) to eliminate free Fluo3-AM, followed by incubation 
with 60 µL per well of recording medium at 37
o
C for 1 h in a 5%CO2 incubator with of 
sample (0.1, 1.0, and 10.0 μg/mL acteoside).  For positive and negative controls, 3 mM Keto. 
and PBS (-) were used, respectively.  The fluorescence intensity (FI) was determined 150 sec 
after adding 0.3 µg/mL of DNP-BSA antigen.  FI was measured at an excitation wavelength 
of 490 nm and emission wavelength of 530 nm using a microplate reader. 
 
Histamine release assay 
The histamine release inhibition assay using KU812 cells was performed as previously 
described [28] and according to the method described by Hosoda et al. [23] with some 
modifications.  KU812 cells were suspended at 2.0 × 10
5
 cells/well in 200 µL of Tyrode 
buffer A (30 mM Tris−HCl, 120 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.6 mM 
glucose, and 0.03% BSA) for treatment with acteoside.  The cells were next incubated with 
or without 25 µL/well of various concentrations of acteoside (0.1-10.0 µg/mL) for 15 min, 
and then stimulated with A23187 (1 µM) plus PMA (20 nM) or compound 48/80 (10 μg/mL) 
for 30 min at 37
o
C.  The cells were separated from the released histamine by centrifugation 
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at 400 x g for 5 min at 4
o
C.  The supernatant (50 µL) was transferred to a 96-well ELISA 
system, and the histamine concentration was determined by ELISA kit according to the 
manufacturer’s instructions.  Histamine EIA kit (Oxford Biomedical Research, USA) were 
used to detect histamine content.  The percentage of histamine released was calculated by 
using the following equation: 
Histamine release (%) = {(T-N) / (C-N)} × 100 
Control (C): A23187+PMA (+) or compound 48/80 (+), test sample (-); Test (T): 
A23187+PMA (+) or compound 48/80 (+), test sample (+); Normal (N): A23187+PAM (-) or 
compound 48/80 (-), test sample (-). 
 
TNF-α and IL-4 production assay 
The TNF-α and IL-4 production inhibition assay using KU812 cells was performed as 
previously described [28].  KU812 cells were seeded onto 96-well plates at 2.0 × 10
5
 
cells/well in 200 µL of medium, incubated with or without acteoside for 15 min and then 
stimulated with A23187 plus PMA for 16 h at 37
o
C, 5%CO2 incubator.  The cells were 
separated from the secreted cytokine by centrifugation at 400 x g for 5 min at 4
o
C.  The 
supernatant (50 and 100 µL) was transferred to a 96-well ELISA system, and the TNF-α level 
and IL-4 concentration were determined by ELISA kit according to the manufacturer’s 
instructions.  Human TNF-α and IL-4 ELISA kit (Biosource International, USA) were used 
to detect TNF-α and IL-4, respectively.  The absorbance at 450 nm was obtained using a 
microplate reader.  To estimate the production of TNF-α or IL-4 by the cells, the same 
procedure was followed, but without the addition of A23187 plus PMA (Normal).  Thus, the 
percentage of TNF-α or IL-4 production was calculated using the following equation.  
Cytokine production (%) = {(T-N) / (C-N)} × 100 
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Control (C): A23187+PMA (+), test sample (-); Test (T): A23187+PMA (+), test sample (+); 
Normal (N): A23187+PMA (-), test sample (-). 
 
Statistical analysis 
Our results are expressed as means ± SD.  The statistical evaluation of the results was 
performed by one-way analysis of variance (ANOVA) followed by Duncan’s post hoc test.  
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Results 
 
We used the MTT assay to assess the cytotoxicity of three phenylethanoid glycosides on 
RBL-2H3 cells and KU812 cells.  The cells were treated with three phenylethanoid for 48 h 
at final concentration of 0.1-100.0 µg/mL.  As show in Fig. 2, the tree phenylethanoid 
glycosides did not cause cytotoxicity at 0.1-10.0 µg/mL.  But, the cell viability of the KU812 
cells were decreased to 90% with the treatment of 100.0 μg/mL acteoside, and the effect being 
significant (p < 0.01, vs. the control value). 
Three phenylethanoid glycosides were screened for their inhibitory effect on 
β-hexosaminidase release by RBL-2H3 cells.  The β-hexosaminidase release from 
IgE-sensitized RBL-2H3 cells were induced by DNP-BSA as a stimulatory antigen.  The 
β-hexosaminidase release from RBL-2H3 cells as affected by three phenylethanoid glycosides 
is shown in Fig. 3.  Three phenylethanoid glycosides showed inhibitory effect on the 
β-hexosaminidase release, the effect being significant at all treatment of acteoside and 
1.0-10.0 μg/mL treatment of cistanoside A (p < 0.05 and p < 0.01 vs. the BSA value).  The 
echinacoside was shown inhibition effect at all treatment, but the effect was not significant 
compared with negative control (BSA).  In the present study, we compared the effect of three 
phenylethanoid glycosides with the clinically available anti-allergic drug, Keto., which is 
known as a mast cell stabilizer, H1-receptor antagonist, eosinophil inhibitor [26].  Kim et al. 
[29] demonstrated that Keto. decrease β-hexosaminidase release and cytoplasm ROS level by 
IgE-mediated RBL-2H3 cells.  The acteoside was the most potent among the three 
compounds at 1.0 μg/mL treatment, showing 29.9% inhibitory effect compared with 3 mM 
Keto. (final 214 μM, IC50=200-300 μM) treatment (inhibition rate was 43.5%) (Fig. 2). 
To examine the relationship between β-hexosaminidase release and [Ca2+]i levels in RBL-2H3 
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cells, we focusing on the acteoside which induced the highest inhibitory effect on 
β-hexosaminidase release, to determined the change in the [Ca2+]i levels.  The increase rate 
of the [Ca
2+
]i level in IgE-mediated RBL-2H3 cells as affected by acteoside is shown in Fig. 4.  
Results reveal that after DNP-BSA stimulation, the cells showed a decrease in [Ca
2+
]i level at 
each acteoside treatment (Fig. 4).  These result was suggest that acteoside suppressed [Ca
2+
]i 
influx in the IgE-sensitized BSA-stimulated RBL-2H3 cells.  The reduction of [Ca
2+
]i levels 
with acteoside at 1.0-10.0 μg/mL treatment was higher than Keto. as positive control. 
To investigate the inhibitory effect of acteoside on human basophilic cells, we examined 
A23187 plus PMA- or compound 48/ 80-induced KU812 cell activation.  First of all, 
inhibitory effects of acteoside on A23187 plus PMA-induced KU812 cell degranulation were 
examined.  Light microscopy photo showed that control KU812 cells generally are spherical 
or oval (Fig. 5A).  After stimulation with A23187 plus PMA, the cell became swollen and 
had many vacuoles and extruded granules near the cell surface and in the surrounding 
medium, which is interpreted as mast cell degranulation (Fig. 5B).  The cells became 
swollen with an irregular boundary, but the degranulation was reduced (Figs. 5C and 5D) by 
preincubation with acteoside in the A23187 plus PMA stimulated KU812 cells. 
The inhibitory effects of acteoside on A23187 plus PMA- or compound 48/80-mediated 
histamine release from KU812 cells are shown in Fig. 6.  Acteoside dose-dependently 
inhibited A23187 plus PMA (Fig. 6A)- or compound 48/80 (Fig. 6B)-mediated histamine 
release in a concentration range of 0.1-10.0 μg/mL.  The histamine release was inhibited 
approximately 63.2, 100.0, and 100.0% after treatment with the acteoside at 0.1-10.0 μg/mL, 
and the effect being significant (p < 0.05, vs. the A23187 plus PMA value).  The histamine 
release was inhibited approximately 100.0, 51.6, and 77.0% after treatment with the acteoside 
at 0.1-10.0 μg/mL, and the effect being significant (p < 0.05, vs. the compound 48/80 value). 
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We examined whether acteoside could regulate inflammatory cytokines such as TNF-α and 
IL-4 in KU812 cells.  The inhibition rate of TNF-α and IL-4 production in A23187 plus 
PMA-stimulated KU812 cells as affected by the acteoside is shown in Fig. 7.  The acteoside 
dose-dependently inhibited the production of TNF-α (Fig. 7A) and IL-4 (Fig. 7B) after 
treatment for 16 h.  The production of the TNF-α was inhibited by about 32.1, 52.1%, and 
the effect being significant (p < 0.05, vs. the A23187 plus PMA).  Furthermore, the 
production of the IL-4 was inhibited by about 14.2, and 80.7% at 1.0 and 10.0 μg/mL 
treatment, and the effect being significant (p <0.05, vs. the A23187 plus PMA) at 10.0 μg/mL 
treatment. 
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Discussion 
 
In this study, phenylethanoid glycosides obtained from Cistanche tubulosa did not affect cell 
viability on RBL-2H3 cells and KU812 cells at the 1.0-10.0 µg/mL treatments.  But, 
acteoside was cytotoxic at the 100.0 µg/mL treatments (Fig. 2B), as has been reported by 
Saracoglu et al. [30] who have shown that acteoside isolated from Phlomic armeniaca and 
Scutellaria salviifolia showed cytotoxic effects on dRLh-84, S-180, P-388/D1 cell lines with 
the IC50 30-221 µg/mL at different cell numbers.  Our result was suggests that inhibition 
effect of actesoide on cell viability at 100 µg/mL treatment, maybe affected by its apoptotic 
activity. 
The immediate-type allergic reaction is involved in many allergic diseases such as asthma, 
allergic rhinitis and sinusitis.  Mast cells play a crucial role in inflammatory and immediate 
allergic responses.  Our data shows that the acteoside has the highest inhibitory effect on the 
β-hexosaminidase release from IgE-sensitized, antigen-stimulated RBL-2H3 cells compared 
with other phenylethanoid glycosides at 1.0 μg/mL treatment (Fig. 3).  Inhibition effect of 
acteoside on β-hexosaminidase release at 10.0 μg/mL treatment was lower than that at 1.0 
μg/mL treatment.  As Sugisawa et al. [31] demonstrated, this may be contributed to H2O2 
induction at high concentrations of acteoside, which might regulated of calcium signals and 
degranulation on the RBL-2H3 cells [32], influenced to β-hexosaminidase release at 10.0 
μg/mL acteoside treatment. 
The degranulation of mast cells is closely related to [Ca
2+
]i.  The inhibition of Ca
2+
 influx by 
anti-allergic drugs plays a crucial role in the suppression of degranulation in mast cells. 
[33-34].  Our results indicate that the intracellular [Ca
2+
]i level was lower in the 
acteoside-treated, DNP-BSA-stimulated RBL-2H3 cells (Fig. 4), which is consistent with 
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other reports [34-35], and these results agree with those of Fig. 3.  We consider from these 
observations that the decrease in intracellular [Ca
2+
]i is involved in the inhibitory effect of 
acteoside on β-hexosaminidase release.  Nitric oxide (NO) and H2O2 are two major reactive 
oxygen species (ROS) known in regulation of calcium signal and degranulation of mast cells.  
ROS are necessary for secretion of β-hexosaminidase and calcium influx, and nicotinamide 
adenin dinucleotide phosphate (NADPH) oxidase is mainly responsible for ROS production 
in the IgE-mediated RBL-2H3 cells [29, 32].  The sustained elevation of cytosolic calcium 
through store-operated calcium entry was totally abolished when the ROS production was 
blocked.  In addition, ROS have some relationship with ß-hexosaminidase and histamine 
release by protein kinase C (PKC) activation and IgE stimulation in RBL-2H3 cells [34].  
Furthermore, Suzuki et al. [36] found that there was a significant correlation between 
inhibition effects on histamine release and 1, 1-diphenyl-2-picry l-hydrazyl (DPPH) or 
superoxide anion radical scavenging activities of curcumin-related anti-oxidant compounds.  
On the other hand, acteoside have free ragical scavenging properties on NO radical and DPPH 
radical [9, 37].  Also acteoside haw shown scavenging activity in activated human 
leucocytes [38].  One of the possibility that inhibition effect of acteoside on intracellular 
calcium release may be affected by its free radical scavenging activities or NADPH oxidase 
activities. 
Acteoside dose-dependently inhibited histamine release on A23187 plus PMA-stimulated 
KU812 cell (Fig. 4A).  Acteoside inhibited glutamate-induced intracellular Ca
2+
 influxes 
resulting in overproduction of NO and reduced formation of ROS [37].  Both PKC and Ca
2+ 
signaling pathways are required for histamine and leukotrienes release from mast cells as well 
as rodent systems [39].  We hypothesized that acteoside may have inhibitory effect on 
histamine release through Ca
2+
 influx.  For this purpose we used A21387 plus PMA to 
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stimulate KU812 cells and demonstrated histamine release inhibition effect with acteoside.  
This result supported our hypothesis that acteoside may decrease histamine release from 
KU812 cells by inhibition of Ca
2+
 influx or PKC activation. 
It is believed without doubt that stimulation of mast cells with compound 48/80 initiates the 
activation of a signal transduction pathway, which leads to histamine release.  Senyshyn et al. 
[40] identified recombinant G subunit markedly synergized phospholipase D activation by 
compound 48/80 in permeabilized basophilic cells.  Compound 48/80-induced secretion is 
associated with a transient increase in cytosolic Ca
2+
.  This secretion was blocked by the 
calcium chelator and PKC inhibitor.  In the present study, we observed that acteoside 
inhibited the compound 48/80-induced degranulation from basophilic cells.  But, inhibition 
effect of acteoside on histamine release at 0.1 μg/mL treatment was higher than that 1.0-10.0 
μg/mL treatment (Fig. 4B).  As Lau et al. [41] demonstrated, inhibition effect of acteoside 
on compound 48/80 induced histamine release may be involved in the anti-inflammation 
effect of acteoside against vascular permeability-associated edema.  Possibly, the acteoside 
may have several different ways of inhibiting chemical mediator release from basophilic cells, 
suggesting the complexity of its action.  However, in order to reveal the mechanism of 
histamine release inhibition of this prescription, further studies should be performed. 
Among cytokines produced by basophilic cells, TNF-α, IL-4, IL-13, and IL-5 are the key 
molecules.  The reduction of pro-inflammatory cytokines from mast cells or basophilic cells 
is one of the key indicators of reduced allergic symptom [42].  With regard to TNF-α, the 
production is mainly regulated by Ca
2+ 
influx, but the release process is regulated by 
additional mechanisms possibly involving activation of PKC in KU812 cells.  Inhibition of 
[Ca
2+
]i influx is involved in the expression of cytokines in mast cells and basophilic cells [34, 
43].  Our result showed that 1.0 and 10.0 µg/mL acteoside reduced TNF-α and IL-4 
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production from A23187 plus PMA stimulated KU812 cells after treatment for 16 h.  
Acteoside might inhibit TNF-α and IL-4 production by decreasing the [Ca2+]i level in A23187 
plus PMA stimulated KU812 cells.  Moreover, our results suggested that the acteoside have 
anti-allergic effect at the late phase.  Confirmation of the effect of acteoside using FcεRI 
expressing mast cells or basophilic cells is necessary in the future. 
In conclusions, we report for the first time that acteoside, echinacoside and cistanoside A 
extracted from Cistanche tubulosa can inhibit the release of β-hexosaminidase from 
IgE-sensitized BSA-stimulated RBL-2H3 cells.  Furthermore, acteoside can inhibit the 
histamine release, TNF-α, and IL-4 production in a dose-dependent manner on A23187 plus 
PMA stimulated KU812 cells.  These results suggest that acteoside could be a good 
candidate for the therapeutic treatment of various allergic diseases.  The detailed mechanism 
behind the anti-allergic affect of acteoside is the subject of a future study. 
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Legends for Figures  
 
Fig. 1  Chemical structure of phenylethanoid glycosides extracted from Cistance tubulosa.  
Acteoside: R
1
 = H, R
2
 = H; Echinacoside: R
1
 = Glc, R
2
 = H; Cistanoside A: R
1
 = Glc, R
2
 = 
CH3. 
 
Fig. 2  Cytotoxic effect of three phenylethanoid glycosides from Cistanche tubulosa on 
RBL-2H3 cells and KU812 cells.  The percent cell viability was calculated relative to the 
untreated cells.  (A) The cell viability of RBL-2H3 cells.  (B) The cell viability of KU812 
cells.  Results represent one trial (n=8).  Three additional trials show similar results.  
**
: 
Statistically significant from the control at p < 0.01. 
 
Fig. 3  Inhibitory effect of three phenylethanoid glycosides from Cistanche tublosa on 
β-hexosaminidase release from RBL-2H3.  Ketotifen fumarate (Keto.) was used as a positive 
control of β-hexosaminidase release.  The cells (5.0 × 104 cells/well) in 100 μL were 
pre-incubated with three kinds of phenylethanoid glycosides at 37
o
C for 10 min prior to their 
incubation with DNP-BSA for 1 h.  Results represent one trial (n=6-8).  Three additional 
trials show similar results.  
*
: Statistically significant from the control at p < 0.05.  
**
: 
Statistically significant from the control at p < 0.01. 
 
Fig. 4  Effect of acteoside extracted from Cistanche tubulosa on the [Ca
+2
]i levels in 
IgE-mediated RBL-2H3 cells.  Ketotifen fumarate salt (Keto.) was used as a positive control 
of [Ca
+2
]i influx.  IgE-sensitized RBL-2H3 cells (5.0 x 10
4
 cells/well) were incubated with 
100 μL of loading buffer including Fluo-3AM for 1 h.  The treated cells were incubated with 
60 μL recording buffer for 30 min.  Changes in [Ca2+]i level induced by DNP-BSA were 
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measured with a microplate reader.  Results represent one trial (n = 3).  2 additional trials 
show similar results.  BSA: Stimulated by DNP-BAS; Keto.: Treatment by ketotifen 
fumarate salt as positive control. 
 
Fig. 5  Light microscopy photo of KU812 cells in medium (A), after stimulation with 
A23187 (1 μM) plus PMA (20 nM) (B), 1.0 μg/mL acteoside prior to the stimulation with 
A23187 plus PMA (C), 10.0 μg/mL acteoside prior to the stimulation with A23187 plus PMA 
(D).  Normal KU812 cells are generally characterized by round shape with fine granules and 
regular surface.  Degranulated basophilic cells become swollen and have many vacuoles, an 
irregular surface and extruded granules.  However, pretreated with acteoside can reduce 
A23187 plus PMA induced degranulation of KU812 cells.  The magnification of the photo 
was x 200.  Bar = 10 μm. 
 
Fig. 6  Inhibitory effect of acteoside on histamine release from KU812 cells after stimulated 
with A23187 (1 μM) plus PMA (20 nM) or compound 48/80 (10 μg/mL).  The cells (2.0 x 
10
5
 cells/well) in 200 μL were preincubated with acteoside at 37oC for 15 min prior to their 
incubation with A23187 plus PMA (A) or compound 48/80 (B).  Results represent one trial 
(n=3).  Two additional trials showed similar results.  
*
: Statistically significant from the 
A23187 plus PMA at p < 0.05. 
 
Fig. 7  Inhibitory effect of acteoside on TNF-α and IL-4 production by KU812 cells after 
stimulation with A23187 plus PMA.  The KU812 cells (2.0 × 10
5
 cells/well) in 200 μL were 
pre-incubated with or without acteoside for 15 min and then stimulated with A23187 (1 μM) 
plus PMA (20 nM) for 16 h.  The production of TNF-α (A) and IL-4 (B) was quantified by 
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ELISA assay.  Results represent two trials (n=4).  
*
: Statistically significant from the 
A23187 plus PMA at p < 0.05. 
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